BioCryst Pharmaceuticals - 53 Year Dividend History | BCRX
Historical dividend payout and yield for BioCryst Pharmaceuticals (BCRX) since 1971. The current TTM dividend payout for BioCryst Pharmaceuticals (BCRX) as of November 20, 2024 is $0.00. The current dividend yield for BioCryst Pharmaceuticals as of November 20, 2024 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Drug Manufacturing |
$1.493B |
$0.331B |
|
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
